Curated News
By: NewsRamp Editorial Staff
August 23, 2024
Diagnostic Stocks Thrive Amid Pandemic Fallout
Discuss on Reddit
Discuss on SubstackTLDR
- Investors can focus on diagnostic companies that have adapted and are now on the upswing, like Exact Sciences (NASDAQ: EXAS).
- Exact Sciences (NASDAQ: EXAS) has developed early cancer screening tests, including a colon cancer screening kit called Cologuard, helping to increase testing volumes.
- Exact Sciences (NASDAQ: EXAS) is contributing to making the world a better place by reinventing themselves and developing early cancer screening tests, aiding in the early detection and treatment of cancer.
- Ludwig Enterprises Inc. (OTCMKTS: LUDG) is a disruptive diagnostic testing company with revolutionary mRNA testing technology that could change the industry.
Impact - Why it Matters
This news matters because the pandemic caused a shift in the diagnostic industry, with some companies successfully adapting by developing early cancer screening tests. As the pandemic ends, these companies are rebounding and may present investment opportunities.
Summary
During the pandemic, many diagnostic companies suffered as regular cancer screenings were put off. However, some companies adapted by developing early cancer screening tests, such as Exact Sciences (NASDAQ: EXAS) and Guardant Health Inc. (NASDAQ: GH). Another key player, Illumina Inc. (NASDAQ: ILMN), spun off its diagnostics business, Grail Inc. (NASDAQ: GRAL), which developed a multi-cancer early detection blood test. Additionally, Ludwig Enterprises Inc. (OTCMKTS: LUDG) is disrupting the sector with mRNA testing technology for less invasive tests, led by an experienced CEO. As the pandemic ends, these companies are on the upswing and worth considering for investment.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Diagnostic Stocks Thrive Amid Pandemic Fallout
